Sildenafil induced choreoathetosis in men with Parkinson's disease

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 1, 2010, Pages 76-78

  Perkovic, Olivio ^a,b   Vitezic, D ^a,b   Rudez, J ^a,b   Vitezic, M ^b   Kovacevic, M ^a,b   Mrsic Pelcic, J ^b   Ljubicic, D ^a,b   Jurjevic, A ^a,b  

^a KBC RIJEKA   (Croatia)

^b UNIVERSITY OF RIJEKA   (Croatia)

Author keywords

Adverse effect; Choreoathetosis; Interaction; Levodopa; Sildenafil

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; DIAZEPAM; HALOPERIDOL; LEVODOPA; SELEGILINE; SILDENAFIL;

ADULT; ANXIETY; ARTICLE; CASE REPORT; CHOREOATHETOSIS; CLINICAL FEATURE; DISEASE PREDISPOSITION; DRUG MEGADOSE; DYSKINESIA; HUMAN; INVOLUNTARY MOVEMENT; MALE; PARKINSON DISEASE; PENIS ERECTION; SEXUAL INTERCOURSE; TREATMENT RESPONSE;

EID: 73649098794     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48076     Document Type: Article

References (14)

1. Hatzichristou DG. Sildenafil citrate: lessons learned from 3 years of clinical experience. Int J Impotence Res. 2002; 14 (Suppl): 43-52.
2. Vitezic D. Arisk-benefit assessment of sildenafil in the treatment of erectile dysfunction. Drug Saf. 2001; 24: 255-265.
3. Vitezic D, Mrsic Pelcic J. Erectile dysfunction: oral pharmacotherapy options. Int J Clin Pharmacol Ther. 2002; 40: 393-403.
4. Hussain IF, Brady CM, Swinn MJ, Mathias CJ, Fowler CJ. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in Parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2001; 71: 371-374.
5. Raffaele R, Vecchio I, Giammusso B, Morgia G, Brunetto MB, Rampello L. Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease. Eur Urol. 2002; 41: 382-386.
6. Zesiewitz A, Helal M, Hauser RA. Sildenafil citrate (Viagra) for the treatment of erectile dysfunctionin men with Parkinson's disease. Mov Disord. 2000; 15: 305-308.
7. Encarnacion EV, Hauser RA. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments. Eur Neurol. 2008; 60: 57-66.
8. Khor SP, Hsu A. The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease. Curr Clin Pharmacol. 2007; 2: 234-243.
9. Munetz MR, Benjamin S. How to examine patients using the abnormal involuntary movement scale. Hosp Community Psychiatry. 1988; 39: 1172-1177.
10. Anonymous. Sildenafil oral: AHFS Detailed Monograph. http://www.medscape.com/druginfo/ monograph?cid=med&drugid=7418&drugname= Sildenafil+Oral&monotype=monograph. Accessed November 30th 2008.
11. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord. 2007; 22: 1379-1389.
12. Mouradian MM, Heuser IJ, Baronti F, Fabbrini G, Juncos JL, Chase TN. Pathogenesis of dyskinesias in Parkinson's disease. Ann Neurol. 1989; 25: 523-526.
13. de la Fuente-Fernández R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, Ruth TJ, Stoessl AJ. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain. 2004; 127: 2747-2754.
14. Zesiewicz TA, Sullivan KL, Hauser RA. Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment. Curr Neurol Neurosci Rep. 2007; 7: 302-310.